Ahammune has advanced its first-in-class drug to solve vitiligo to mid-trials with a fraction of the cost of global peers. It’s not been an easy road, but the tide is turning.
Ahammune has advanced its first-in-class drug to solve vitiligo to mid-trials with a fraction of the cost of global peers. It’s not been an easy road, but the tide is turning. by Soban News (international And National News)
